The CIMP subtype in prostate cancer shows decreased expression of tumor suppressor genes and has been associated with distinct clinical features, including higher Gleason score, higher PSA, higher tumor grade, and overall poor outcome. The gene discussed is KLK3; the disease is prostate cancer.